Basic Information
| Drug ID | DDPD01201 |
|
| Drug Name | Rifapentine | |
| Molecular Weight | 877.0307 | |
| Molecular Formula | C47H64N4O12 | |
| CAS Number | 61379-65-5 | |
| SMILES | CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O | |
| External Links | ||
| DRUGBANK | DB01201 | |
| T3DB | T3D3018 | |
| PubChem Compound | 6323497 | |
| PDR | 1035 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 4.0 | - | 4.0 | - | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Clearance | 2.5 | L/h | 2.51±0.14 | L/h | apparent clearance; PO, oral; Drug combination; tuberculosis; patients; Male, men; | DRUGBANK | Clearance | 1.7 | L/h | 1.69±0.41 | L/h | apparent clearance; PO, oral; Drug combination; tuberculosis; patients; Female, women; | DRUGBANK |
| Volume of Distribution | 70.2 | L | 70.2±9.1 | L | DRUGBANK | |
| Eliminate Route | 17.0 | % | 17 | % | Urinary excretion; Oral single dose; normal,healthy; human, homo sapiens; | DRUGBANK | Eliminate Route | 70.0 | % | 70 | % | Faeces excretion; Oral single dose; normal,healthy; human, homo sapiens; | DRUGBANK |
| Protein Binding | 97.7 | % | 97.7 | % | plasma proteins; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 900.0 | mg/dose | 900 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for children | 750.0 | mg/dose | 750 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for children | 600.0 | mg/dose | 600 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for children | 450.0 | mg/dose | 450 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for children | 300.0 | mg/dose | 300 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for adolescents | 900.0 | mg/dose | 900 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for adolescents | 750.0 | mg/dose | 750 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for adolescents | 600.0 | mg/dose | 600 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for adults | 900.0 | mg/dose | 900 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
| Max dose for geriatric | 900.0 | mg/dose | 900 | mg/dose | PO, oral | Priftin | rifapentine | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1